All In Biotech

Drug Trial Radar · NCT03466346

SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project

A Sequential, Multiple Assignment Randomized Trial (SMART) for Non-specialist Treatment of Common Mental Disorders in Kenya: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (DAPPER) Project

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,162

Actual

Start

Aug 31, 2020

Primary completion

May 6, 2024

Study completion May 6, 2024

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Nairobi; National Institute of Mental Health (NIMH); Kenya Medical Research Institute; University of California, San Diego; Makerere University
First posted
Mar 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite carrying the vast majority of the global mental disorder burden, 75% of adults with mental disorders in Low and Middle Income Countries have no access to services. This study will test strategies for integrating first and second line evidence-based depression and trauma-related disorder treatments with primary care services at a large public sector hospital and conduct robust cost and cost-benefit analyses of each treatment to produce a "menu" of cost-benefit options for personalized, integrated mental health care with corresponding effectiveness and implementation values.

Conditions

  • Depression, Unipolar
  • Posttraumatic Stress Disorder
  • Trauma

Interventions

  • FluoxetineDrug

    Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.

  • Interpersonal PsychotherapyBehavioral

    IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Major Depression at End of TreatmentTime frame: End of 1st line Treatment (up to month 6) and end of 2nd line Treatment (up to month 12)
  2. Number of Participants With PTSDTime frame: End of 1st line Treatment (up to month 6) and end of 2nd line Treatment (up to month 12)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH)

    Kisumu, Kenya

  • Kisumu County Hospital

    Kisumu, Kenya

  • Lumumba Health Center

    Kisumu, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.